Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings

Mina C. Hosseinipour, Ravindra K. Gupta, Gert Van Zyl, Joseph J. Eron, Jean B. Nachega

Research output: Contribution to journalArticle

Abstract

IntroductionAntiretroviral therapy (ART) in resource-limited settings has expanded in the last decade, reaching >8 million individuals and reducing AIDS mortality and morbidity. Continued success of ART programs will require understanding the emergence of HIV drug resistance patterns among individuals in whom treatment has failed and managing ART from both an individual and public health perspective. We review data on the emergence of HIV drug resistance among individuals in whom first-line therapy has failed and clinical and resistance outcomes of those receiving second-line therapy in resource-limited settings.ResultsResistance surveys among patients initiating first-line nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based therapy suggest that 76%-90% of living patients achieve HIV RNA suppression by 12 months after ART initiation. Among patients with detectable HIV RNA at 12 months, HIV drug resistance, primarily due to M184V and NNRTI mutations, has been identified in 60%-72%, although the antiretroviral activity of proposed second-line regimens has been preserved. Complex mutation patterns, including thymidine-analog mutations, K65R, and multinucleoside mutations, are prevalent among cases of treatment failure identified by clinical or immunologic methods. Approximately 22% of patients receiving second-line therapy do not achieve HIV RNA suppression by 6 months, with poor adherence, rather than HIV drug resistance, driving most failures. Major protease inhibitor resistance at the time of second-line failure ranges from 0% to 50%, but studies are limited.ConclusionsResistance of HIV to first-line therapy is predictable at 12 months when evaluated by means of HIV RNA monitoring and, when detected, largely preserves second-line therapy options. Optimizing adherence, performing resistance surveillance, and improving treatment monitoring are critical for long-term prevention of drug resistance.

Original languageEnglish (US)
JournalJournal of Infectious Diseases
Volume207
Issue numberSUPPL.2
DOIs
StatePublished - Jun 15 2013

Fingerprint

Drug Resistance
HIV
RNA
Mutation
Reverse Transcriptase Inhibitors
Therapeutics
Protease Inhibitors
Treatment Failure
Thymidine
Acquired Immunodeficiency Syndrome
Public Health
Morbidity
Mortality

Keywords

  • antiretroviral drug resistance
  • resource-limited settings
  • second-line therapy

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy

Cite this

Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings. / Hosseinipour, Mina C.; Gupta, Ravindra K.; Van Zyl, Gert; Eron, Joseph J.; Nachega, Jean B.

In: Journal of Infectious Diseases, Vol. 207, No. SUPPL.2, 15.06.2013.

Research output: Contribution to journalArticle

Hosseinipour, Mina C. ; Gupta, Ravindra K. ; Van Zyl, Gert ; Eron, Joseph J. ; Nachega, Jean B. / Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings. In: Journal of Infectious Diseases. 2013 ; Vol. 207, No. SUPPL.2.
@article{a48c07dd24a64f81b01198120157248f,
title = "Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings",
abstract = "IntroductionAntiretroviral therapy (ART) in resource-limited settings has expanded in the last decade, reaching >8 million individuals and reducing AIDS mortality and morbidity. Continued success of ART programs will require understanding the emergence of HIV drug resistance patterns among individuals in whom treatment has failed and managing ART from both an individual and public health perspective. We review data on the emergence of HIV drug resistance among individuals in whom first-line therapy has failed and clinical and resistance outcomes of those receiving second-line therapy in resource-limited settings.ResultsResistance surveys among patients initiating first-line nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based therapy suggest that 76{\%}-90{\%} of living patients achieve HIV RNA suppression by 12 months after ART initiation. Among patients with detectable HIV RNA at 12 months, HIV drug resistance, primarily due to M184V and NNRTI mutations, has been identified in 60{\%}-72{\%}, although the antiretroviral activity of proposed second-line regimens has been preserved. Complex mutation patterns, including thymidine-analog mutations, K65R, and multinucleoside mutations, are prevalent among cases of treatment failure identified by clinical or immunologic methods. Approximately 22{\%} of patients receiving second-line therapy do not achieve HIV RNA suppression by 6 months, with poor adherence, rather than HIV drug resistance, driving most failures. Major protease inhibitor resistance at the time of second-line failure ranges from 0{\%} to 50{\%}, but studies are limited.ConclusionsResistance of HIV to first-line therapy is predictable at 12 months when evaluated by means of HIV RNA monitoring and, when detected, largely preserves second-line therapy options. Optimizing adherence, performing resistance surveillance, and improving treatment monitoring are critical for long-term prevention of drug resistance.",
keywords = "antiretroviral drug resistance, resource-limited settings, second-line therapy",
author = "Hosseinipour, {Mina C.} and Gupta, {Ravindra K.} and {Van Zyl}, Gert and Eron, {Joseph J.} and Nachega, {Jean B.}",
year = "2013",
month = "6",
day = "15",
doi = "10.1093/infdis/jit107",
language = "English (US)",
volume = "207",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "SUPPL.2",

}

TY - JOUR

T1 - Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings

AU - Hosseinipour, Mina C.

AU - Gupta, Ravindra K.

AU - Van Zyl, Gert

AU - Eron, Joseph J.

AU - Nachega, Jean B.

PY - 2013/6/15

Y1 - 2013/6/15

N2 - IntroductionAntiretroviral therapy (ART) in resource-limited settings has expanded in the last decade, reaching >8 million individuals and reducing AIDS mortality and morbidity. Continued success of ART programs will require understanding the emergence of HIV drug resistance patterns among individuals in whom treatment has failed and managing ART from both an individual and public health perspective. We review data on the emergence of HIV drug resistance among individuals in whom first-line therapy has failed and clinical and resistance outcomes of those receiving second-line therapy in resource-limited settings.ResultsResistance surveys among patients initiating first-line nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based therapy suggest that 76%-90% of living patients achieve HIV RNA suppression by 12 months after ART initiation. Among patients with detectable HIV RNA at 12 months, HIV drug resistance, primarily due to M184V and NNRTI mutations, has been identified in 60%-72%, although the antiretroviral activity of proposed second-line regimens has been preserved. Complex mutation patterns, including thymidine-analog mutations, K65R, and multinucleoside mutations, are prevalent among cases of treatment failure identified by clinical or immunologic methods. Approximately 22% of patients receiving second-line therapy do not achieve HIV RNA suppression by 6 months, with poor adherence, rather than HIV drug resistance, driving most failures. Major protease inhibitor resistance at the time of second-line failure ranges from 0% to 50%, but studies are limited.ConclusionsResistance of HIV to first-line therapy is predictable at 12 months when evaluated by means of HIV RNA monitoring and, when detected, largely preserves second-line therapy options. Optimizing adherence, performing resistance surveillance, and improving treatment monitoring are critical for long-term prevention of drug resistance.

AB - IntroductionAntiretroviral therapy (ART) in resource-limited settings has expanded in the last decade, reaching >8 million individuals and reducing AIDS mortality and morbidity. Continued success of ART programs will require understanding the emergence of HIV drug resistance patterns among individuals in whom treatment has failed and managing ART from both an individual and public health perspective. We review data on the emergence of HIV drug resistance among individuals in whom first-line therapy has failed and clinical and resistance outcomes of those receiving second-line therapy in resource-limited settings.ResultsResistance surveys among patients initiating first-line nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based therapy suggest that 76%-90% of living patients achieve HIV RNA suppression by 12 months after ART initiation. Among patients with detectable HIV RNA at 12 months, HIV drug resistance, primarily due to M184V and NNRTI mutations, has been identified in 60%-72%, although the antiretroviral activity of proposed second-line regimens has been preserved. Complex mutation patterns, including thymidine-analog mutations, K65R, and multinucleoside mutations, are prevalent among cases of treatment failure identified by clinical or immunologic methods. Approximately 22% of patients receiving second-line therapy do not achieve HIV RNA suppression by 6 months, with poor adherence, rather than HIV drug resistance, driving most failures. Major protease inhibitor resistance at the time of second-line failure ranges from 0% to 50%, but studies are limited.ConclusionsResistance of HIV to first-line therapy is predictable at 12 months when evaluated by means of HIV RNA monitoring and, when detected, largely preserves second-line therapy options. Optimizing adherence, performing resistance surveillance, and improving treatment monitoring are critical for long-term prevention of drug resistance.

KW - antiretroviral drug resistance

KW - resource-limited settings

KW - second-line therapy

UR - http://www.scopus.com/inward/record.url?scp=84878333879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878333879&partnerID=8YFLogxK

U2 - 10.1093/infdis/jit107

DO - 10.1093/infdis/jit107

M3 - Article

C2 - 23687289

AN - SCOPUS:84878333879

VL - 207

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - SUPPL.2

ER -